NewsBenzingaMiMedx Group reduce su previsión de ventas para el año fiscal 2026 de $260.000M-$290.000M a $250.000M-$260.000M frente a los $267.018M estimados MiMedx Group reduce su previsión de ventas para el año fiscal 2026 de $260.000M-$290.000M a $250.000M-$260.000M frente a los $267.018M estimados Benzinga 2026.10.28 20:13 (GMT+0) Open on Benzinga Other news StoneX Maintains Buy on Rivian Automotive, Lowers Price Target to $20 Amer Sports Unleashes $1 Billion Buyback, Raises 2026 Outlook EXCLUSIVE: Tesla Still Rules Leveraged ETFs, but Anthropic IPO and Micron’s Rise Signal What’s Next StoneX Reiterates Hold on iQIYIto Hold StoneX Maintains Buy on Baidu, Lowers Price Target to $125 Veru Presents New Results At ObesityWeek; Adding Enobosarm Preserved Lean Mass And Stair Climb Physical Function In Older Patients ≥65 Years With Obesity Receiving Semaglutide
Veru Presents New Results At ObesityWeek; Adding Enobosarm Preserved Lean Mass And Stair Climb Physical Function In Older Patients ≥65 Years With Obesity Receiving Semaglutide